Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T63237
|
|||||
| Target Name |
17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13)
|
|||||
| Synonyms |
17-beta-HSD 13; Hepatic retinol/retinal dehydrogenase; Short chain dehydrogenase/reductase family 16C member 3; Short-chain dehydrogenase/reductase 9
Click to Show/Hide
|
|||||
| Gene Name |
HSD17B13
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Non-alcoholic fatty liver disease [ICD-11: DB92] | |||||
| Function |
Plays a pivotal role in hepatic lipid metabolism (PubMed:29562163). In vitro, it catalyzes the oxidation of a variety of lipid substrates, including 17beta-estradiol, retinol, retinal, and leukotriene B4 (PubMed:29562163, PubMed:30415504, PubMed:32973038). {ECO:0000269|PubMed:29562163, ECO:0000269|PubMed:30415504, ECO:0000269|PubMed:32973038}.; [Isoform 2]: Has retinol/retinal dehydrogenase activity in vitro. {ECO:0000269|PubMed:30415504, ECO:0000269|PubMed:32973038}.; [Isoform 1]: Does not have retinol/retinal dehydrogenase activity in vitro. {ECO:0000269|PubMed:30415504}.
Click to Show/Hide
|
|||||
| UniProt ID | ||||||
| EC Number |
EC 1.1.1.-; EC 1.1.1.105; EC 1.1.1.62
|
|||||
| Sequence |
MNIILEILLLLITIIYSYLESLVKFFIPQRRKSVAGEIVLITGAGHGIGRQTTYEFAKRQ
SILVLWDINKRGVEETAAECRKLGVTAHAYVVDCSNREEIYRSLNQVKKEVGDVTIVVNN AGTVYPADLLSTKDEEITKTFEVNILGHFWITKALLPSMMERNHGHIVTVASVCGHEGIP YLIPYCSSKFAAVGFHRGLTSELQALGKTGIKTSCLCPVFVNTGFTKNPSTRLWPVLETD EVVRSLIDGILTNKKMIFVPSYINIFLRLQKFLPERASAILNRMQNIQFEAVVGHKIKMK Click to Show/Hide
|
|||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | GSK4532990 | Drug Info | Phase 2 | Non-alcoholic steatohepatitis | [2] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Silencer | [+] 1 Silencer drugs | + | ||||
| 1 | GSK4532990 | Drug Info | [1] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Arrowhead Pharmaceuticals | |||||
| REF 2 | ClinicalTrials.gov (NCT05583344) 17 beta-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Pre-Cirrhotic Nonalcoholic Steatohepatitis. U.S.National Institutes of Health. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.